Leave Your Message

He Manaʻo Kūʻokoʻa o ka Lapaʻau Leukemia

ʻO CAR-T Therapy, pōkole no ka Chimeric Antigen Receptor T-Cell Immunotherapy, he ʻano hana hoʻōla ʻano holomua e pili ana i ka hoʻololi ʻana i nā pūnaewele T ponoʻī o ka mea maʻi e hoʻopaʻa ʻia a luku i nā maʻi maʻi. ʻAʻole like me nā lāʻau lapaʻau maʻamau, ua hoʻohālikelike ʻia ka lāʻau lapaʻau CAR-T i kēlā me kēia maʻi a pono e hōʻiliʻili i nā pūnae T mai ke koko o ka mea maʻi ma mua o ka hoʻihoʻi ʻana iā lākou i loko o ke kino ma hope o ka ʻenekinia genetic.

    Nā hōʻailona o CAR-T

    B-cell acute lymphoblastic leukemia

    ʻO ka myeloma lehulehu

    Leukemia lymphocytic mau loa

    ʻO ka lymphoma non-Hodgkin

    Hoʻolahalaha nui B-cell lymphoma

    SLE (Systemic Lupus Erythematosus)

    ʻO Myasthenia gravis

    ʻO nā maʻi autoimmune ʻē aʻe

    Hana maikaʻi ʻo CAR-T

    Nā hōʻailona no CD19+20CAR-T:ʻO nā poʻe maʻi me B-cell non Hodgkin's lymphoma

    Hoʻokahi mahina CR uku

    Hoʻokahi mahina PR uku

    Hoʻokahi mahina OR uku

    CRS≥3

    CRES≥3

    71.95% (59/82)

    25.6 (21/82)

    97.55 (80/82)

    12.19% (10/82)

    0

    Nā hōʻailona no CD19+22CAR-T:Hoʻomaʻamaʻa ʻana i nā maʻi maʻi maʻi maʻi leukemia B-lymphocytic acute CD19

    Hoʻokahi mahina CR uku

    Hoʻokahi mahina PR uku

    Hoʻokahi mahina OR uku

    CRS≥3

    CRES≥3

    92.1% (35/38)

    7.9% (3/38)

    100% (38/38)

    15.79% (6/38)

    0

    Nā hōʻailona no BCMACAR-T:Ka mālama ʻana i ka myeloma lehulehu i hoʻihoʻi hou ʻia

    Hoʻokahi mahina CR uku

    Hoʻokahi mahina PR uku

    Hoʻokahi mahina OR uku

    CRS≥3

    CRES≥3

    72.41% (21/29)

    27.59% (8/29)

    100% (29/29)

    6.9% (2/29)

    0

    CAR-T THERAPY KAHIKI (2)tch

    ʻO kā mākou pono

     Hoʻoponopono pilikino: Hoʻopilikino ʻia kēlā me kēia lāʻau lapaʻau CAR-T i ka mea maʻi, e hōʻoia ana i nā hopena lapaʻau i manaʻo nui ʻia a maikaʻi.

     Nā Koho Huhu Hoʻokaʻawale: Me ka laulā o nā antigens target, e like me CD7, CD19, CD20, CD22, a me BCMA, hāʻawi kā mākou huahana CAR-T i ka versatility i hiki ʻole ke hoʻohālikelike i ka mālama ʻana i nā maʻi maʻi hematological a me nā maʻi autoimmune.

     Hōʻoiaʻiʻo ʻia i ka holomua o ke kino: Ua hōʻike ko mākou mau lāʻau lapaʻau CAR-T i ka maikaʻi ʻokoʻa ma waena o nā hihia lapaʻau he nui, me ka nui o ke kala kala ʻana a me nā kiʻi palekana, e hoʻoikaika ana i ko mākou kūlana ma ke ʻano he alakaʻi i ka immunotherapy.

     Kiʻekiʻe Kūʻai-Elele: Hāʻawi mākou i kahi hoʻokūkū hoʻokūkū me nā lāʻau lapaʻau ʻoi aku ka maikaʻi ma ke kumu kūʻai hiki ke hoʻohālikelike ʻia me nā huahana CAR-T ʻē aʻe ma ka mākeke.

     ʻenehana ʻokiʻoki: Ke hoʻohana nei i nā holomua hou loa i ka ʻenekinia genetic, ʻo kā mākou CAR-T therapies e hoʻokomo i ka wā e hiki mai ana o ka maʻi kanesa a me ka mālama ʻana i nā maʻi autoimmune.

     Kākoʻo Kauka Manaʻo: Hāʻawi kā mākou hui loea o nā kauka a me nā mea noiʻi i ka mālama piha ʻana mai ke kūkākūkā mua ʻana ma o ka hoʻokele therapy a me ka hahai ʻana.

    Ua ʻike nui ʻia nā cell CAR-T i kēia manawa no ko lākou pono i nā poʻe maʻi i pane ʻole i nā lāʻau kuʻuna e like me ka chemotherapy a i ʻole ka hoʻololi ʻana i ka iwi iwi. Hoʻomaopopo ka poʻe olakino olakino i ka hiki ke hoʻomaka ʻia o ka CAR-T therapy i ka hoʻololi ʻana i nā hopena maʻi.

    wehewehe2

    Fill out my online form.